FDA approves abatacept for prophylaxis of acute graft versus host disease

On December 15, 2021, the Food and Drug Administration approved abatacept (Orencia, Bristol-Myers Squibb Company) for the prophylaxis of acute graft versus host disease (aGVHD)

Source: FDA Center for Drug Evaluation and Research - What's New - December 15, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news